Do Cancer and Cancer Treatments Accelerate Aging?

Introduction

Advances in detection and therapeutics have dramatically increased survival after cancer over the last quarter of the century. In fact, 70% of cancer survivors will be alive 5 or more years from diagnosis, and nearly 18% will survive 20 years or longer [ 1 ]. By 2030, it is estimated that the population of cancer survivors will exceed 22 million [ 1 ].

Despite improvements in survival, over two-thirds of all cancer survivors will have at least one chronic health condition—some because of cancer therapy itself [ 2 ]. While age is a risk factor for the development of cancer, the treatment of cancer, including chemotherapy, immunotherapy, surgery, and radiation therapy, can also accelerate biological aging processes. Furthermore, childhood cancer survivors are noted to develop twice the burden of disease by age of 45 compared to non-cancer controls [ 3 ]. On average, they are found to have seven or more chronic diseases compared to the generalized population, two of which will be seriously disabling, life-threatening, or fatal [ 3 ].

Cancer survivors are thought to develop two kinds of comorbidities: early-onset conditions, or those associated with acute effects of cancer therapy; and late-occurring conditions, or those occurring at longer-term follow-up and typically increase with age, at a faster rate compared to the generalized population [ 3 ]. Examples of these late-occurring effects include frailty [ 4 ], sarcopenia [ 5 ], cardiac dysfunction [ 5 ], and mild cognitive impairment [ 7 ].

The late occurrence of these comorbidities that happen earlier or more frequently in cancer survivors compared to cancer-free individuals is cumulatively summed up as accelerated aging [ 8 ]. The mechanisms behind accelerated aging are likely multifactorial and remain to be clearly elucidated. However, cancer and aging are thought to share several hallmarks including genomic instability, telomere attrition, and epigenetic alterations which may be implicated in accelerated aging [ 9 ]. Furthermore, treatment with cytotoxic therapy can compound these changes potentially also contributing to accelerated aging.

Herein, we aim to review the evidence to understand how and if cancer patients experience accelerated aging, the cellular mechanisms which may contribute to this phenomenon, and possible interventions to reduce the rate of or to completely reverse the phenomenon in cancer survivors.

Hallmarks of Normal Aging

Normal aging represents the inevitable, time-dependent decline in physiologic organ function and is characterized by nine hallmarks [ 10 ]. These hallmarks are summarized in Table 1 . Aggravation of these characteristics may accelerate normal aging while amelioration is thought to decelerate the aging process thereby increasing the healthy lifespan. To illustrate, exposures such as ultraviolet radiation or ionizing radiation can induce cellular DNA damage which cause cell senescence contributing to aging [ 11 ]. On the other hand, aerobic exercise can maintain genomic stability by augmenting DNA repair [ 12 ]. Table 1 Shared hallmarks between aging and cancer Hallmark Aging Cancer & cancer therapeutics 1. Genomic instability The general cause of aging is widely considered to be the accumulation of cellular damage. The stability of DNA is continuously under threat due to exogenous (physical, chemical, biological agents) and endogenous threats (DNA replication errors, reactive oxygen species) Cellular damage to oncogenes and tumor suppressor genes can give rise to cancer Defects in DNA surveillance mechanisms such as DNA repair machinery can further result in genomic instability and predispose to malignant transformation 2. Telomere attrition Accumulation of DNA damage is widespread throughout the genome; however, telomeres are particularly susceptible to age-related deterioration. Telomerase is an enzyme that augments cellular lifespan and the deficiency of which is associated with premature development of diseases due to a decrease in the regenerative capacity of tissues Cancer cells possess high telomerase activity and are characterized by perpetuality in undergoing cell division Some chemotherapies such as cisplatin and 4-hydroperoxycyclophosphamide can directly impair telomerase in malignant and non-malignant cells 3. Epigenetic alterations Involve age-associated changes in DNA methylation patterns, post-translational medication of histones, and chromatin remodeling Epigenetic changes can influence cancer development in 3 ways: -Inducing mutations in genes associated with cell cycle regulation -Promoting genomic instability -Activation of proto-oncogenes and de-activation of tumor suppressor genes 4. Impaired proteostasis Proteostasis involves mechanisms for the stabilization of correctly folded proteins and mechanisms for the degradation of proteins by proteosome or lysosome. This process is altered in aging (Koga et al. 2011) Certain chemotherapeutic agents such as ixazomib in multiple myeloma impair protein folding and thus cause apoptosis of malignant cells 5. Deregulated nutrient sensing: Genetic polymorphisms which reduce the function of growth hormone, insulin-like growth factor 1 (IGF-1) produced in response to GH, or downstream intracellular effectors such as AKT, mTOR, and FOXO have been linked to longevity due to being associated with lower rates of cell growth, metabolism and, hence, lower rates of cellular damage Inhibitors of mTOR such as everolimus are used for treatment of breast cancer and renal cell carcinoma. However, use of these agents can also lead to impaired wound healing, insulin resistance, cataracts, and testicular degeneration and thus promotion of the aging phenotype 6. Cellular senescence Defined as the stable arrest of the cell cycle. The primary purpose of the senescence is to prevent the propagation of damaged cells and trigger their demise by the immune system. Senescent cells differ in their secretory phenotype which is particularly enriched in proinflammatory cytokines and this may contribute to aging. Furthermore, the levels of p16 INK4a robustly correlate with chronic age in humans Inflammatory secretome associated with senescent cells can have varying impacts on pre-malignant and malignant cells: -Either prevent pre-malignant cells from realizing their malignant potential OR -Promote a cancer conducive microenvironment The outcome of this inflammatory state depends on specific tissue, genome and/or external stimuli 7. Stem cell exhaustion Represents the functional decline in stem cell function Rapamycin, an inhibitor of MTOR, has been shown to promote cellular longevity, perhaps by activating genes in stem cells that can respond to oxidative stress (which otherwise are downregulated with aging and thus cause stem cell exhaustion). Rapamycin has been shown to prolong life in mice Given deregulated mTOR signaling in tumors, everolimus and other mTOR inhibitors are being studied for use in cancer treatment 8. Altered intercellular communication Represents changes to intercellular communication including in endocrine, neuroendocrine, and neuronal pathways often described as “inflammaging,” or a proinflammatory phenotype associated with aging Immunotherapy can stimulate intercellular communication in promoting tumor resistance and expression of this proinflammatory phenotype has been associated with aging 9. Mitochondrial dysfunction: As cells and organisms age, the efficacy of respiratory chain is diminished and there is an increase in the accumulation of reactive oxygen species Genetic damage leading to alterations in function of mitochondria has been associated with both cancer and aging. Mutations to mitochondrial DNA have been associated with cancer progression in various malignancies. In addition, a leading theory postulates that many cancers exhibit a depleted mitochondrial DNA content at the expense of the upregulation of genes associated with cell cycle propagation

Shared Cellular Hallmarks Between Aging, Cancer, and Cancer Therapeutics

Over the last 10 years, treatments for hematologic and solid tumor malignancies have been revolutionized through targeted therapies and immunotherapy. However, despite continued efforts to focus treatment in a manner that spares healthy cells and tissues, damage can still occur, contributing to the aging phenotype [ 13 •]. The mechanisms by which this can happen are described in detail below and summarized in Fig. 1 . Cellular senescence: defined as the stable arrest of the cell cycle. In addition to apoptosis, cellular senescence inhibits unchecked growth of cells. Senescent cells have a different “secretome” as described in Table 1 compared to non-senescent cells that mirror inflammatory responses and are crucial for the induction and maintenance of senescence. Its impact on cancer development is twofold: on one hand, this inflammatory cascade can prevent pre-malignant cells from realizing their full malignant potential by promoting its clearance. On the other hand, inflammatory cytokines and chemokines can also provide a cancer-promoting microenvironment for neighboring pre-malignant and malignant epithelial cells. Thus, the overall impact depends on the specific tissue, its genome, and external stimuli [ 14 ]. Chemotherapy, CDK4/6 inhibitors, and immunotherapy aim to induce senescence in tumor cells, but they can also exert a similar cellular senescence in adjacent non-tumor tissues [ 15 ]. The associated inflammatory cascade associated with senescent cells in tumor-adjacent cells can itself lead to accelerated aging [ 16 , 17 ]. Telomere attrition: telomerase is an enzyme which is associated with telomere lengthening and thereby cellular propagation. Inhibition of telomerase and the resultant short telomeres prevent uncontrolled cell proliferation. When telomere length reaches a critical size, DNA damage occurs, and replicative senescence is achieved. Cancer cells possess high telomerase activity and they are characterized by their infinite ability to replicate [ 18 ]. Cancer treatments such as azidothymidine (AZT) and tamoxifen can directly impair telomerase [ 19 ]. Indirect effects of chemotherapy on shortening telomeres have also been described in patients with hematologic and solid tumor malignancies, thus accelerating aging in cancer survivors [ 20 ]. Genomic instability: defects in DNA surveillance mechanisms (DNA repair machinery, DNA damage checkpoint) can result in genomic instability, thus predisposing the cell to malignant transformation. Radiation therapy can cause direct DNA damage [ 21 ]. In addition, chemotherapeutic agents such as cisplatin can generate reactive oxygen species as intermediates which can also cause DNA damage [ 22 ]. Epigenetic alterations: epigenetic phenomena such as histone modifications, DNA methylation, and microRNAs can influence the formation of cancer in multiple ways: (i) it can induce point mutations which can cause changes in the function of genes regulating the cell cycle; (ii) it can cause genomic instability, leading to chromosomal breaks, allelic loss, and translocations which is characteristic of many malignancies; and (iii) it can activate/deactivate gene transcription for example of proto-oncogenes and tumor suppressor genes. Epigenetic age acceleration (EAA) is the deviation between the estimated epigenetic age and chronological age and represents the general health status or rate of physiologic aging. To ascertain such physiologic aging, several DNA-based “epigenetic clocks” have been proposed and demonstrated strong associations with various age-related chronic health diseases [ 23 ]. Studies of childhood cancer survivors show that they have a higher annual change in EAA compared to non-cancer controls, and this accelerated change persists throughout their lifetimes [ 24 ••]. Furthermore, exposure to various cancer therapies can contribute to the heightened EAAs in cancer survivors. For example, alkylating agents, topoisomerase inhibitors, doxorubicin, methotrexate, and radiation therapy can lead to DNA hypermethylation and lead to accelerated aging phenotype [ 24 ••, 25 ]. The mechanism for this phenomenon remains poorly understood. Loss of proteostasis: due to a loss of ability to maintain correctly folded proteins, and degrade nonfunctional or unnecessary proteins, loss of proteostasis can lead to increased cellular apoptosis and is a mechanism leveraged by some cancer therapeutics such as ixazomib which is used in the treatment for multiple myeloma [ 13 •]. Deregulated nutrient sensing: everolimus is a mTOR inhibitor with multiple indications including in breast cancer, renal cell carcinoma, and neuroendocrine tumors. However, its use is also associated with the aging phenotype in mice models due to impaired wound healing, insulin resistance, cataracts, and testicular degeneration [ 26 ]. Altered intercellular communication: immunotherapy such as PD-1 blockade which has ever-broadening indications can stimulate intercellular communication, and is associated with a proinflammatory phenotype associated with aging [ 13 •]. Fig. 1 Normal aging versus accelerated aging

Indirect Impacts of Cancer and Its Therapy

Cancer patients experience worse quality of life, lost productivity, and increased psychosocial distress and anxiety compared to non-cancer controls [ 27 ••, 28 ]. Furthermore, heightened levels of psychosocial stress are linked to the activation of the sympathetic nervous system and the hypothalamic–pituitary–adrenal (HPA) axis which mediate the release of downstream catecholamines and cortisol. Higher circulating levels of these stress hormones increase the risk of biological aging in three ways: (i) increased cellular metabolic activity, which increases the production of reactive oxygen species which can cause genomic instability as previously described; (ii) cellular damage, or the ability of glucocorticoids to decrease telomerase activity, leading to cellular senescence; and (iii) glucocorticoids are thought to impair DNA repair pathways. This damage can drive inflammatory changes in the nearby tissue microenvironment that is characteristic of senescent cells. Furthermore, stress hormones themselves are associated with an increase in the production of proinflammatory cytokines by leading to the upregulation of inflammation-promoting transcription factors such as NF-KB, AP1, and CREB. This cumulative upregulation in inflammation can result in accelerated aging [ 29 •].

Cancer patients may also develop malnutrition due to adverse effects from chemotherapy and/or radiation due to altered sense of taste and smell, food aversions, nausea/vomiting, mucositis, constipation, diarrhea, and early satiety, consequently leading to weight loss. In one retrospective study of 191 cancer patients aged 28–72 years old, weight loss was observed in 40–90% of cancer patients receiving chemotherapy (depending on cancer location) [ 30 ]. In addition, chemotherapy has also been found to have a direct effect on muscle loss independent of weight. For example, cisplatin, irinotecan, doxorubicin, and etoposide cause direct muscle loss by activating transcription factors such as NF-KB and tumor growth factor which upregulate proteolysis and inflammatory cytokines, accelerating muscle catabolism [ 31 ].

Malnutrition is associated with early treatment discontinuation and heightened risk of chemotherapy toxicity, which can lead to accelerated aging as described above [ 32 ].

In one study of 114 patients with metastatic colorectal cancer, malnutrition was associated with more adverse effects after chemotherapy, especially hematologic and gastrointestinal side effects [ 33 ]. This may be partially explained by the dysbiosis of the gut microbiome, a dynamic endocrine entity that is highly receptive to changes in diet and other lifestyle factors. Chemotherapy has been shown to alter the microbiome, including reducing the diversity of microbes, which has been associated with intestinal inflammation and characteristically found in obese or elderly patients [ 34 ]. However, the gut microbiome also regulates the metabolism of immunotherapy and many common chemotherapies (cisplatin, oxaliplatin, doxorubicin, cyclophosphamide), including the development of treatment-related toxicity [ 35 ]. Therefore, it can be imagined that the development of malnutrition (likely multifactorial) may also lead to accelerated aging due to dysbiosis and which can further lead to treatment-associated toxicity (which thereby leads to a cycle of accelerated aging). On the other hand, modulation of the gut microbiome by the use of probiotics has been associated with the prevention of treatment-related toxicity in colorectal cancer [ 36 ].

Unfortunately, the impact of chemoradiotherapy on nutrition may not subside after the completion of treatment. Some studies suggest that chemotherapy and radiation treatments may also be associated with long-term sequelae leading to poor nutritional status. In 40 patients with stage III-IV head and neck cancer assessed at a median follow-up of 44 months post-chemoradiotherapy, 75% experienced dysphagia, and 19% were at risk of malnutrition. All the participants were forced to implement dietary restrictions. Furthermore, their intake of a balanced diet of vitamins and minerals was found to be far below recommended levels [ 37 ].

Although a direct mechanism remains to be clearly elucidated, by leading to weight loss, sarcopenia, and long-term nutritional deficits, cancer treatments such as chemoradiotherapy certainly appear to add fuel to the fire that is aging.

Clinical Manifestations of Accelerated Aging

Frailty

Frailty is a state of reduced physiologic reserve which occurs as a result of normal aging. Clinically, frailty is used to identify cancer patients at high risk for poor outcomes, and after cancer therapy to identify survivors at risk for early morbidity and mortality, also known as Fried’s criteria [ 38 ]. However, there is no standard instrument to identify frailty; rather, its assessment spans multiple domains including physical performance (as delineated by performance on the 6-min walk test, get up and go test, gait speed), strength (grip strength), nutritional status, and cognition and is characterized by an accumulating deficit approach (e.g., totaling up the number of tasks or activities that a patient is not able to do). Furthermore, as it is a dynamic process, patients may move in and out of frail states throughout their lifetimes.

Between 9 and 59% of cancer survivors have been classified as frail in epidemiologic studies—nearly quadruple the rates of frailty compared to non-cancer survivors in analyses matched by age, sex, and race [ 39 – 42 ]. Female cancer survivors are more likely to be frail [ 43 ], which may be partially attributable to their capacity to regenerate muscles [ 44 ]. Moreover, cancer treatments acting on hormonal axes (e.g., androgen deprivation therapy in prostate cancer, estrogen antagonists such as aromatase inhibitors) may exacerbate frailty [ 45 ]. Cancer treatment that involves operative procedures can initiate a cascade of cytokine releases including IL-6 and C-reactive protein (CRP) which may induce proinflammatory changes conducive to aging [ 46 ].

Among childhood cancer survivors, those with malignancies involving the brain, bone, or Hodgkin’s lymphoma were at the most risk of developing frailty [ 43 , 47 ]. Cancer treatment–associated predictors of frailty in survivors are listed in Fig. 1 .

Identifying Cancer Patients Most at Risk of Developing Frailty

P16ink4a is a biomarker whose expression increases with chronologic age, and it may serve as a robust biomarker of molecular aging [ 48 ]. In studies of patients receiving chemotherapy, p16ink4a expression increased exponentially after treatment and remained elevated at 12 months post-treatment [ 49 ]. Some have considered this increase to represent a 10–15-year increase in chronologic age [ 50 ], and measuring levels of this biomarker pre- and post-treatment may help oncologists predict which patients may develop treatment-associated frailty. For example, Smitherman et al. [ 51 ] found that among children and young adult cancer survivors, chemotherapy was associated with higher p16ink4a levels. Frail survivors exhibited higher levels of p16ink4a levels compared to robust survivors; this higher expression of p16ink4a was found to represent an average 25-year age acceleration in frail survivors [ 51 ].

Interleukin (IL) 6 has been a well-studied inflammatory biomarker shown to be correlated with frailty [ 52 ], and has been shown to predict functional decline including the capacity to carry out activities of daily living and development of poor mobility [ 53 ].

Inflammaging/Metaflammation

Aside from cancer therapy–related changes in left ventricular ejection fraction (for example, due to anthracyclines), cancer survivors living at least 5 years beyond diagnosis face up to a threefold higher risk of cardiovascular-specific mortality and up to an 18-fold increase in risk factors for cardiovascular disease such as hypertension, diabetes mellitus, and dyslipidemia compared to age-matched counterparts without a history of cancer [ 54 , 55 ]. This is likely a result of both age coupled with direct (chemotherapy, radiation, targeted therapy) and indirect (frailty, weight gain) effects of cancer therapy [ 56 , 57 ].

Indeed, studies of cardiorespiratory fitness (CRF), an integrative assessment of global cardiovascular function, demonstrate cancer treatment–associated decline and reduced recovery after treatment [ 58 , 59 ]. To illustrate, patients with breast cancer have 30–32% lower mean CRF levels compared to age-matched, healthy, sedentary , control subjects [ 60 ]. Similar phenomena have been illustrated in young adult cancer survivors [ 61 ], and in patients with gynecologic cancers [ 59 ]. In fact, among cancer survivors, peak exercise capacity (V02 peak) is reduced by an average of 20% at mean follow-up after 34 months of chemotherapy [ 62 ]. Furthermore, cancer survivors have been shown to have low physical activity levels, with up to 75% of survivors not achieving recommended guidelines [ 63 ]. Yet as few as 20% of oncologists routinely discuss lifestyle guidance in survivorship [ 64 ]. Thus, chronic low physical activity, coupled with increasing chronologic age, coupled with late effects of cancer treatment can all compound to lower CRF.

However, undergoing aerobic and resistance training in cancer survivors has been associated with improvement in CRF. Among 152 breast cancer survivors (most of whom had completed therapy), participation in a once-a-week, supervised exercise regimen focused on aerobic and resistance training resulted in significant improvement in CRF, quality of life, and fatigue [ 65 ]. In another study of cancer survivors, participation in aerobic and resistance training was associated with improved 6-min walk duration, 1-repetition maximum leg press, and arm strength [ 66 ].

As a result, the American Society of Clinical Oncology (ASCO) has issued a practice guideline to better identify cancer survivors who may benefit from cardiac rehab to reduce their risk of cardiac dysfunction. The following patients should be considered for high risk of cardiac dysfunction and thus meriting a referral for cardiac rehab [ 67 ]: (1) treatment with high-dose anthracycline or high-dose radiotherapy when the heart is in the treatment field or lower-dose anthracycline in combination with lower-dose radiotherapy; OR (2) treatment with lower-dose anthracycline or trastuzumab alone plus the presence of ≥ 2 risk factors (smoking, hypertension, diabetes mellitus, obesity, dyslipidemia), ≥ 60 years at cancer treatment, or compromised cardiac function; OR (3) treatment with lower-dose anthracycline followed by trastuzumab.

Can Accelerated Aging Be Reversed or Decelerated?

Given that a higher number of cancer survivors are living longer and aging into older adulthood, evidence-based strategies to mitigate the aging consequences of cancer and cancer treatment described above are desperately needed. However, there are limited data on how physical activity and dietary strategies may avert or ameliorate accelerated aging associated with cancer or its treatment. Furthermore, how diet and exercise may impact biomarkers associated with aging remains to be investigated [ 27 ••].

The Role of Diet

Animal models suggest that caloric restriction can slow biological aging and can not only delay the onset of cancer but also can delay the onset of cardiovascular disease, diabetes, and neurodegenerative disorders and prolong overall lifespan [ 68 , 69 ]. Furthermore, during the last decades, diet and nutrition have been implicated in cancer risk, progression, and treatment response through acting on shared aging pathways described above including telomerase activity, bioenergetics, DNA repair, and oxidative stress [ 70 ]. To illustrate, it is estimated that 30–40% of cancers can be prevented by lifestyle choices including a healthy diet, improved physical activity, and prevention of obesity and overweight. Studies of immigrants suggest that migration is associated with altered cancer risk compared to the country of origin. For example, first-generation Japanese women in the USA have a threefold increase in breast cancer compared to women living in Japan [ 71 ]. Similarly, studies of European migrants to Australia showed a higher risk of colorectal cancer (similar to Australian-born population) but a diminished risk of stomach cancer (similar to Australian-born population), proportional to the migrants’ duration in the country [ 72 ]. It is thought that these alterations in cancer risk are at least partially due to dietary acculturation.

Furthermore, calorie restriction (CR), or reduction in dietary intake by 30% without causing malnutrition, has been postulated to curb excess adiposity and thus decrease the level of oxidative stress that promotes tumorigenesis [ 73 ]. In vitro studies suggest that CR can not only halt tumor progression but also increase lifespan in experimental animal models [ 74 ]. In a prostate cancer mouse model, calorie restriction decreased tumor weight and plasma insulin levels as well as decreased IGF-1 signaling which was correlated with higher apoptosis levels [ 75 ]. In human studies, 15% caloric reduction over 4 years showed a decrease in the growth factors cascade associated with increased risk of cancer [ 74 ]. Another study of calorie restriction over a 2-year period in humans demonstrated a reduction in markers of oxidative stress associated with tumorigenesis [ 76 ].

Thus, diet and nutrition can alter both cancer and aging outcomes. Yet simply recommending dieting and/or fasting can be challenging in patients with malignancies due to the occurrence of sarcopenia and sarcopenic obesity associated with both cancer and its treatment [ 77 ]. Additionally, the relationship between diet, nutrition, aging, and the long-term effects of cancer and cancer treatment is not well understood.

Yet, there is evidence to suggest that diet modulation before cancer treatment may help reduce treatment-associated toxicity, improve treatment specificity for the tumor, and reduce treatment effect on non-cancerous healthy tissue, thereby improving survival [ 78 – 81 ]. For example, in a randomized trial of patients with gynecologic cancer, patients who fasted 36 h prior to chemotherapy and 24 h post-chemotherapy demonstrated better chemotherapy tolerance, higher quality of life, and ability to participate in their activities of daily living, and less fatigue than control patients [ 82 ].

Furthermore, in particular, whey protein supplementation during cancer treatment has been associated with improved physical performance in cancer patients [ 83 – 85 ]. In one randomized double-controlled study, 40 mg of whey protein supplementation per week for 12 weeks between chemotherapy cycles for patients with non-metastatic solid tumor malignancies led to statistically significant increases in serum albumin levels compared to control, which are reflective of general nutritional status [ 83 ]. In another randomized study of malnourished patients (> 10% unintentional weight loss over 6 months prior to the study) with a mix of advanced solid tumor malignancies, 20 mg of whey protein daily for 3 months led to statistically significant increases in muscle strength, body weight, and decreased risk of chemotherapy toxicity compared to the control arm [ 85 ].

The mechanism may be through improvement in lean body mass, sarcopenia, muscle strength, and functional capacity thereby attenuating frailty and preventing chemotherapy toxicity. However, there is also evidence of increased IGF-related signaling associated with an increase in protein intake in mouse models that could on the contrary increase tumor growth by inhibiting apoptosis which must be weighed against any positive supplementation effects, but this effect has not been observed in human studies and is of unknown significance [ 86 ].

The Role of Exercise

In addition to being safe and cost-effective, prior studies indicate exercise can mitigate several hallmarks of aging [ 87 ] and can prevent diet-induced cellular senescence [ 88 ]. Furthermore, studies of exercise “prehabilitation” (e.g., exercise before cancer surgery or adjuvant treatment) demonstrates that it can not only improve cardiorespiratory fitness [ 89 ], but can also lower post-operative complications [ 90 ], and support recovery post-treatment, thereby attenuating a frail state. Furthermore, exercise during and after cancer treatment is associated with a reduction in functional decline because of improved cardiovascular health and maintenance of lean muscle mass [ 91 , 92 ].

Moreover, it may also modulate tumor biology to increase delivery to the receptiveness of chemotherapy as was seen in patients with pancreatic cancer who participated in a pilot exercise program and went on to demonstrate a differential tumor vascular remodeling which was associated with increased chemotherapy efficacy in the experimental group [ 91 ]. In addition to pancreatic cancer, there is evidence of similar exercise-associated tumor remodeling in prostrate [ 93 ], breast [ 94 ], melanoma [ 95 ], and Ewing sarcoma tumors [ 96 ]. In the murine model of Ewing Sarcoma, moderate aerobic exercise was associated with increased delivery of chemotherapy to the tumor but not to other organs suggesting that exercise may increase chemotherapy specificity for the tumor and may mitigate the toxicity to non-cancerous tissue thereby reducing the propensity of age-associated changes in healthy tissues as has been described above.

Senolytics

One area of ongoing research centers on developing pharmacologic models to selectively reduce senescent cells. Senolysis has gained traction in recent years as a potential method to reverse age-related changes. Among the agents being studied are dasatinib and quercetin, whose senolytic effect is thought to be related to the selective clearance of senescent cells in the bone marrow by induction of apoptosis [ 97 ]. In addition, studies of an anti-inflammatory agent, fisetin, are also being conducted in childhood cancer survivors to understand if they can lower frailty and other markers of inflammation including insulin resistance and bone resorption [ 98 ].

Conclusion

In summary, this review summarizes both the direct and indirect mechanisms by which cancer and its treatment can accelerate aging. In essence, cancer treatment including chemotherapy and immunotherapy can induce senescence in adjacent non-malignant cells which can propagate an inflammatory cascade associated with aging. In addition, radiation and chemotherapy can lead to genomic instability due to either direct DNA damage (radiation) or the creation of intermediary reactive oxygen species which can subsequently also induce replicative senescence as cellular DNA damage accumulates. Indirectly, patients with cancer experience an upregulated HPA axis which leads to downstream production of catecholamines and cortisol which can further amplify the risk of accelerated aging due to increased metabolic activity, induction of cellular damage, and impairment of DNA repair pathways. However, modulation of diet and exercise, including caloric restriction, whey protein supplementation, and aerobic exercise are just a few of the interventions being studied to reverse or mitigate the accelerated aging seen in patients with cancer.

This article is part of the Topical collection on Geriatric Oncology

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Declarations

Conflict of Interest

Roma Bhatia declares that she has no conflict of interest. Shernan Holtan has received Research Funding from Incyte Corporation and VITRAC Therapeutics; has received clinical trial adjudication fees from CSL Behring; and has received compensation for service on scientific advisory boards from Generon and Ossium Health. Najla El Jurdi declares that she has no conflict of interest. Anna Prizment declares that she has no conflict of interest. Anne Blaes declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

1. Cancer Treatment and Survivorship Facts and Figures 2019–2021. American Cancer Society 2019. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2019-2021.pdf

2. Guy GP Jr Yabroff KR Ekwueme DU Rim SH Li R Richardson LC Economic burden of chronic conditions among survivors of cancer in the United States J Clin Oncol 2017 35 18 2053 2061 28471724 10.1200/JCO.2016.71.9716 PMC6059377

3. Bhakta N Liu Q Ness KK The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE) Lancet 2017 390 10112 2569 2582 28890157 10.1016/S0140-6736(17)31610-0 PMC5798235

4. Ness KK Morris EB Nolan VG Physical performance limitations among adult survivors of childhood brain tumors Cancer 2010 116 12 3034 3044 20564409 10.1002/cncr.25051 PMC3554250

5. Ness KK Howell CR Bjornard KL Frailty and quality of life in adult survivors of childhood cancer Expert Rev Qual Life Cancer Care 2017 2 2 79 85 28451645 10.1080/23809000.2017.1300507 PMC5402753

6. Armenian SH Lacchetti C Barac A Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 2017 35 8 893 911 27918725 10.1200/JCO.2016.70.5400

7. Lange M Joly F Vardy J Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors Ann Oncol 2019 30 12 1925 1940 31617564 10.1093/annonc/mdz410 PMC8109411

8. Henderson TO, Ness KK, Cohen HJ. Accelerated aging among cancer survivors: from pediatrics to geriatrics. Am Soc Clin Oncol Educ Book. 2014:e423–30. 10.14694/EdBook_AM.2014.34.e423 10.14694/EdBook_AM.2014.34.e423 24857133

9. Aunan JR Cho WC Soreide K The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks Aging Dis 2017 8 5 628 642 28966806 10.14336/AD.2017.0103 PMC5614326

10. Lopez-Otin C Blasco MA Partridge L Serrano M Kroemer G The hallmarks of aging Cell 2013 153 6 1194 1217 23746838 10.1016/j.cell.2013.05.039 PMC3836174

11. Hoeijmakers JH DNA damage, aging, and cancer N Engl J Med 2009 361 15 1475 1485 19812404 10.1056/NEJMra0804615

12. Radak Z Naito H Kaneko T Exercise training decreases DNA damage and increases DNA repair and resistance against oxidative stress of proteins in aged rat skeletal muscle Pflugers Arch 2002 445 2 273 278 12457248 10.1007/s00424-002-0918-6

13. Hill A Sadda J LaBarge MA Hurria A How cancer therapeutics cause accelerated aging: insights from the hallmarks of aging J Geriatr Oncol 2020 11 2 191 193 30905710 10.1016/j.jgo.2019.03.007

14. Ren JL Pan JS Lu YP Sun P Han J Inflammatory signaling and cellular senescence Cell Signal 2009 21 3 378 383 18992324 10.1016/j.cellsig.2008.10.011 PMC2870712

15. Wang B Kohli J Demaria M Senescent cells in cancer therapy: friends or foes? Trends Cancer 2020 6 10 838 857 32482536 10.1016/j.trecan.2020.05.004

16. Campisi J Aging, cellular senescence, and cancer Annu Rev Physiol 2013 75 685 705 23140366 10.1146/annurev-physiol-030212-183653 PMC4166529

17. Coppe JP Desprez PY Krtolica A Campisi J The senescence-associated secretory phenotype: the dark side of tumor suppression Annu Rev Pathol 2010 5 99 118 20078217 10.1146/annurev-pathol-121808-102144 PMC4166495

18. Trybek T Kowalik A Gozdz S Kowalska A Telomeres and telomerase in oncogenesis Oncol Lett 2020 20 2 1015 1027 32724340 10.3892/ol.2020.11659 PMC7377093

19. Zhang RG Zhang RP Wang XW Xie H Effects of cisplatin on telomerase activity and telomere length in BEL-7404 human hepatoma cells Cell Res 2002 12 1 55 62 11942411 10.1038/sj.cr.7290110

20. Lee JJ Nam CE Cho SH Park KS Chung IJ Kim HJ Telomere length shortening in non-Hodgkin’s lymphoma patients undergoing chemotherapy Ann Hematol 2003 82 8 492 495 12910376 10.1007/s00277-003-0691-4

21. Whitaker SJ DNA damage by drugs and radiation: what is important and how is it measured? Eur J Cancer 1992 28 1 273 276 1567678 10.1016/0959-8049(92)90432-2

22. Levine EG Bloomfield CD Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure Semin Oncol 1992 19 1 47 84 1736370

23. Horvath S DNA methylation age of human tissues and cell types Genome Biol 2013 14 10 R115 24138928 10.1186/gb-2013-14-10-r115 PMC4015143

24. Qin N Li Z Song N Epigenetic age acceleration and chronic health conditions among adult survivors of childhood cancer J Natl Cancer Inst 2021 113 5 597 605 32970815 10.1093/jnci/djaa147 PMC8096366

25. Johnson AA Akman K Calimport SR Wuttke D Stolzing A de Magalhaes JP The role of DNA methylation in aging, rejuvenation, and age-related disease Rejuvenation Res 2012 15 5 483 494 23098078 10.1089/rej.2012.1324 PMC3482848

26. Wilkinson JE Burmeister L Brooks SV Rapamycin slows aging in mice Aging Cell 2012 11 4 675 682 22587563 10.1111/j.1474-9726.2012.00832.x PMC3434687

27. Guida JL Agurs-Collins T Ahles TA Strategies to prevent or remediate cancer and treatment-related aging J Natl Cancer Inst 2021 113 2 112 122 32348501 10.1093/jnci/djaa060 PMC7850536

28. Carreira H Williams R Muller M Harewood R Stanway S Bhaskaran K Associations between breast cancer survivorship and adverse mental health outcomes: a systematic review J Natl Cancer Inst 2018 110 12 1311 1327 30403799 10.1093/jnci/djy177 PMC6292797

29. Carroll JE Bower JE Ganz PA Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care Nat Rev Clin Oncol 2022 19 3 173 187 34873313 10.1038/s41571-021-00580-3 PMC9974153

30. Sanchez-Lara K Ugalde-Morales E Motola-Kuba D Green D Gastrointestinal symptoms and weight loss in cancer patients receiving chemotherapy Br J Nutr 2013 109 5 894 897 22691288 10.1017/S0007114512002073

31. Davis MP Panikkar R Sarcopenia associated with chemotherapy and targeted agents for cancer therapy Ann Palliat Med 2019 8 1 86 101 30525762 10.21037/apm.2018.08.02

32. Caillet P Liuu E Raynaud Simon A Association between cachexia, chemotherapy and outcomes in older cancer patients: a systematic review Clin Nutr 2017 36 6 1473 1482 28017447 10.1016/j.clnu.2016.12.003

33. Barret M Malka D Aparicio T Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study Oncology 2011 81 5–6 395 402 22269999 10.1159/000335478

34. Montassier E Gastinne T Vangay P Chemotherapy-driven dysbiosis in the intestinal microbiome Aliment Pharmacol Ther 2015 42 5 515 528 26147207 10.1111/apt.13302

35. Roy S Trinchieri G Microbiota: a key orchestrator of cancer therapy Nat Rev Cancer 2017 17 5 271 285 28303904 10.1038/nrc.2017.13

36. Chang CW Liu CY Lee HC Lactobacillus casei variety rhamnosus probiotic preventively attenuates 5-fluorouracil/oxaliplatin-induced intestinal injury in a syngeneic colorectal cancer model Front Microbiol 2018 9 983 29867884 10.3389/fmicb.2018.00983 PMC5962742

37. van den Berg MG Rutten H Rasmussen-Conrad EL Nutritional status, food intake, and dysphagia in long-term survivors with head and neck cancer treated with chemoradiotherapy: a cross-sectional study Head Neck 2014 36 1 60 65 23559543 10.1002/hed.23265

38. Hoogendijk EO Afilalo J Ensrud KE Kowal P Onder G Fried LP Frailty: implications for clinical practice and public health Lancet 2019 394 10206 1365 1375 31609228 10.1016/S0140-6736(19)31786-6

39. Franco I Chen YH Chipidza F Use of frailty to predict survival in elderly patients with early stage non-small-cell lung cancer treated with stereotactic body radiation therapy J Geriatr Oncol 2018 9 2 130 137 28941581 10.1016/j.jgo.2017.09.002

40. Arora M Sun CL Ness KK Physiologic frailty in nonelderly hematopoietic cell transplantation patients: results from the bone marrow transplant survivor study JAMA Oncol 2016 2 10 1277 1286 27254472 10.1001/jamaoncol.2016.0855 PMC5078990

41. Brown JC Harhay MO Harhay MN The prognostic importance of frailty in cancer survivors J Am Geriatr Soc 2015 63 12 2538 2543 26566767 10.1111/jgs.13819 PMC4688177

42. Bylow K Hemmerich J Mohile SG Stadler WM Sajid S Dale W Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study Urology 2011 77 4 934 940 21269665 10.1016/j.urology.2010.11.024 PMC3074039

43. Ness KK Krull KR Jones KE Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study J Clin Oncol 2013 31 36 4496 4503 24248696 10.1200/JCO.2013.52.2268 PMC3871511

44. Phung LA Karvinen SM Colson BA Thomas DD Lowe DA Age affects myosin relaxation states in skeletal muscle fibers of female but not male mice PLoS ONE 2018 13 9 e0199062 30226869 10.1371/journal.pone.0199062 PMC6143227

45. Chemaitilly W Li Z Krasin MJ Premature ovarian insufficiency in childhood cancer survivors: a report from the St. Jude lifetime cohort J Clin Endocrinol Metab 2017 102 7 2242 2250 28368472 10.1210/jc.2016-3723 PMC5505200

46. Watt DG Horgan PG McMillan DC Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: a systematic review Surgery 2015 157 2 362 380 25616950 10.1016/j.surg.2014.09.009

47. Hayek S Gibson TM Leisenring WM Prevalence and predictors of frailty in childhood cancer survivors and siblings: a report from the childhood cancer survivor study J Clin Oncol 2020 38 3 232 247 31800343 10.1200/JCO.19.01226 PMC6968796

48. Liu Y Sanoff HK Cho H Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging Aging Cell 2009 8 4 439 448 19485966 10.1111/j.1474-9726.2009.00489.x PMC2752333

49. Sanoff HK Deal AM Krishnamurthy J Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer J Natl Cancer Inst 2014 106 4 dju057 24681605 10.1093/jnci/dju057 PMC3982894

50. Hurria A Jones L Muss HB Cancer treatment as an accelerated aging process: assessment, biomarkers, and interventions Am Soc Clin Oncol Educ Book 2016 35 e516 e522 27249761 10.1200/EDBK_156160

51. Smitherman AB Wood WA Mitin N Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16(INK4a) and frailty Cancer 2020 126 22 4975 4983 32830315 10.1002/cncr.33112 PMC7607511

52. Franceschi C Campisi J Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases J Gerontol A Biol Sci Med Sci 2014 69 Suppl 1 S4 9 24833586 10.1093/gerona/glu057

53. Ferrucci L Penninx BW Volpato S Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels J Am Geriatr Soc 2002 50 12 1947 1954 12473005 10.1046/j.1532-5415.2002.50605.x

54. Hooning MJ Botma A Aleman BM Long-term risk of cardiovascular disease in 10-year survivors of breast cancer J Natl Cancer Inst 2007 99 5 365 375 17341728 10.1093/jnci/djk064

55. Chow EJ Mueller BA Baker KS Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation Ann Intern Med 2011 155 1 21 32 21727290 10.7326/0003-4819-155-1-201107050-00004

56. Baker KS Ness KK Steinberger J Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study Blood 2007 109 4 1765 1772 17047152 10.1182/blood-2006-05-022335 PMC1794046

57. Jones LW Haykowsky MJ Swartz JJ Douglas PS Mackey JR Early breast cancer therapy and cardiovascular injury J Am Coll Cardiol 2007 50 15 1435 1441 17919562 10.1016/j.jacc.2007.06.037

58. Peel AB Thomas SM Dittus K Jones LW Lakoski SG Cardiorespiratory fitness in breast cancer patients: a call for normative values J Am Heart Assoc 2014 3 1 e000432 24419734 10.1161/JAHA.113.000432 PMC3959685

59. Peel AB Barlow CE Leonard D DeFina LF Jones LW Lakoski SG Cardiorespiratory fitness in survivors of cervical, endometrial, and ovarian cancers: the Cooper Center Longitudinal Study Gynecol Oncol 2015 138 2 394 397 26026734 10.1016/j.ygyno.2015.05.027

60. Jones LW Courneya KS Mackey JR Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum J Clin Oncol 2012 30 20 2530 2537 22614980 10.1200/JCO.2011.39.9014 PMC3397786

61. Miller AM Lopez-Mitnik G Somarriba G Exercise capacity in long-term survivors of pediatric cancer: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study Pediatr Blood Cancer 2013 60 4 663 668 23255294 10.1002/pbc.24410

62. Jones LW Haykowsky M Pituskin EN Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor–positive operable breast cancer Oncologist 2007 12 10 1156 1164 17962609 10.1634/theoncologist.12-10-1156

63. Mizrahi D Fardell JE Wakefield CE How physically active do Australian and New Zealander childhood cancer survivors perceive themselves? A report from the ANZCHOG survivorship study Complement Ther Med 2019 44 196 203 31126556 10.1016/j.ctim.2019.04.020

64. Demark-Wahnefried W Aziz NM Rowland JH Pinto BM Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer J Clin Oncol 2005 23 24 5814 5830 16043830 10.1200/JCO.2005.01.230 PMC1550285

65. Dolan LB Barry D Petrella T The cardiac rehabilitation model improves fitness, quality of life, and depression in breast cancer survivors J Cardiopulm Rehabil Prev 2018 38 4 246 252 28525464 10.1097/HCR.0000000000000256

66. Dittus KL Lakoski SG Savage PD Exercise-based oncology rehabilitation: leveraging the cardiac rehabilitation model J Cardiopulm Rehabil Prev 2015 35 2 130 139 25407596 10.1097/HCR.0000000000000091 PMC4342296

67. Gilchrist SC Barac A Ades PA Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association Circulation 2019 139 21 e997 e1012 30955352 10.1161/CIR.0000000000000679 PMC7603804

68. Hursting SD Lavigne JA Berrigan D Perkins SN Barrett JC Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans Annu Rev Med 2003 54 131 152 12525670 10.1146/annurev.med.54.101601.152156

69. Longo VD Mattson MP Fasting: molecular mechanisms and clinical applications Cell Metab 2014 19 2 181 192 24440038 10.1016/j.cmet.2013.12.008 PMC3946160

70. Riscuta G Nutrigenomics at the interface of aging, lifespan, and cancer prevention J Nutr 2016 146 10 1931 1939 27558581 10.3945/jn.116.235119 PMC5037878

71. Kolonel LN Nomura AM Hinds MW Hirohata T Hankin JH Lee J Role of diet in cancer incidence in Hawaii Cancer Res 1983 43 5 Suppl 2397s 2402s 6831463

72. McMichael AJ McCall MG Hartshorne JM Woodings TL Patterns of gastro-intestinal cancer in European migrants to Australia: the role of dietary change Int J Cancer 1980 25 4 431 437 7372370 10.1002/ijc.2910250402

73. Gray A Dang BN Moore TB Clemens R Pressman P A review of nutrition and dietary interventions in oncology SAGE Open Med 2020 8 2050312120926877 32537159 10.1177/2050312120926877 PMC7268120

74. Longo VD Fontana L Calorie restriction and cancer prevention: metabolic and molecular mechanisms Trends Pharmacol Sci 2010 31 2 89 98 20097433 10.1016/j.tips.2009.11.004 PMC2829867

75. Galet C Gray A Said JW Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts Int J Mol Sci 2013 14 7 13782 13795 23823800 10.3390/ijms140713782 PMC3742217

76. Redman LM Heilbronn LK Martin CK Metabolic and behavioral compensations in response to caloric restriction: implications for the maintenance of weight loss PLoS ONE 2009 4 2 e4377 19198647 10.1371/journal.pone.0004377 PMC2634841

77. Carneiro IP Mazurak VC Prado CM Clinical implications of sarcopenic obesity in cancer Curr Oncol Rep 2016 18 10 62 27541923 10.1007/s11912-016-0546-5

78. Lu Z Xie J Wu G Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation Nat Med 2017 23 1 79 90 27941793 10.1038/nm.4252 PMC6956990

79. Caffa I D'Agostino V Damonte P Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition Oncotarget 2015 6 14 11820 32 25909220 10.18632/oncotarget.3689 PMC4494907

80. Bianchi G Martella R Ravera S Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models Oncotarget 2015 6 14 11806 19 25909219 10.18632/oncotarget.3688 PMC4494906

81. Brandhorst S Wei M Hwang S Morgan TE Longo VD Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression Exp Gerontol 2013 48 10 1120 1128 23454633 10.1016/j.exger.2013.02.016 PMC3762887

82. Bauersfeld SP Kessler CS Wischnewsky M The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study BMC Cancer 2018 18 1 476 29699509 10.1186/s12885-018-4353-2 PMC5921787

83. Bumrungpert A Pavadhgul P Nunthanawanich P Sirikanchanarod A Adulbhan A Whey protein supplementation improves nutritional status, glutathione levels, and immune function in cancer patients: a randomized, double-blind controlled trial J Med Food 2018 21 6 612 616 29565716 10.1089/jmf.2017.4080

84. Mazzuca F Roberto M Arrivi G Clinical impact of highly purified, whey proteins in patients affected with colorectal cancer undergoing chemotherapy: preliminary results of a placebo-controlled study Integr Cancer Ther 2019 18 1534735419866920 31370717 10.1177/1534735419866920 PMC6681246

85. Cereda E Turri A Klersy C Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy Cancer Med 2019 8 16 6923 6932 31568698 10.1002/cam4.2517 PMC6853834

86. Nencioni A Caffa I Cortellino S Longo VD Fasting and cancer: molecular mechanisms and clinical application Nat Rev Cancer 2018 18 11 707 719 30327499 10.1038/s41568-018-0061-0 PMC6938162

87. Garatachea N Pareja-Galeano H Sanchis-Gomar F Exercise attenuates the major hallmarks of aging Rejuvenation Res 2015 18 1 57 89 25431878 10.1089/rej.2014.1623 PMC4340807

88. Schafer MJ White TA Evans G Exercise prevents diet-induced cellular senescence in adipose tissue Diabetes 2016 65 6 1606 1615 26983960 10.2337/db15-0291 PMC4878429

89. Stefanelli F Meoli I Cobuccio R High-intensity training and cardiopulmonary exercise testing in patients with chronic obstructive pulmonary disease and non-small-cell lung cancer undergoing lobectomy Eur J Cardiothorac Surg 2013 44 4 e260 e265 23892298 10.1093/ejcts/ezt375

90. Sebio Garcia R Yanez Brage MI Gimenez Moolhuyzen E Granger CL Denehy L Functional and postoperative outcomes after preoperative exercise training in patients with lung cancer: a systematic review and meta-analysis Interact Cardiovasc Thorac Surg 2016 23 3 486 497 27226400 10.1093/icvts/ivw152

91. Scott JM Zabor EC Schwitzer E Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis J Clin Oncol 2018 36 22 2297 2305 29894274 10.1200/JCO.2017.77.5809 PMC6804903

92. Focht BC Clinton SK Devor ST Resistance exercise interventions during and following cancer treatment: a systematic review J Support Oncol 2013 11 2 45 60 23967493

93. McCullough DJ Stabley JN Siemann DW Behnke BJ Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise J Natl Cancer Inst 2014 106 4 dju036 24627275 10.1093/jnci/dju036 PMC3982888

94. Betof AS, Lascola CD, Weitzel D, et al. Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. J Natl Cancer Inst. May 2015;107(5) 10.1093/jnci/djv040 10.1093/jnci/djv040 PMC4822524 25780062

95. Schadler KL Thomas NJ Galie PA Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy Oncotarget 2016 7 40 65429 65440 27589843 10.18632/oncotarget.11748 PMC5323166

96. Morrell MBG Alvarez-Florez C Zhang A Vascular modulation through exercise improves chemotherapy efficacy in Ewing sarcoma Pediatr Blood Cancer 2019 66 9 e27835 31136074 10.1002/pbc.27835 PMC6646082

97. Shimizu I Minamino T Cellular senescence in cardiac diseases J Cardiol 2019 74 4 313 319 31202488 10.1016/j.jjcc.2019.05.002

98. An open-label intervention trial to reduce senescence and improve frailty in adult survivors of childhood cancer. ClinicalTrials.gov; 2022. https://clinicaltrials.gov/ct2/show/NCT04733534